Ionis Pharmaceuticals IONS Available-for-Sale Debt Securities - Unrealized Loss Position
Available-for-Sale Debt Securities - Unrealized Loss Position at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position?
- Ionis Pharmaceuticals (IONS) reported available-for-sale debt securities - unrealized loss position of $2.73M in Q1 2026.
- How has Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position changed year-over-year?
- Ionis Pharmaceuticals's available-for-sale debt securities - unrealized loss position increased by 58.3% year-over-year, from $1.73M to $2.73M.
- What does available-for-sale debt securities - unrealized loss position mean?
- The total value of all debt investments currently trading below their original cost.
- How do you interpret available-for-sale debt securities - unrealized loss position?
- An increase reflects broader market pressure on the company's fixed-income holdings.
- How does available-for-sale debt securities - unrealized loss position compare across companies?
- Standard across all industries that maintain significant corporate treasury investment portfolios.